|
1
|
Schoeffler AJ and Berger JM: DNA
topoisomerases: Harnessing and constraining energy to govern
chromosome topology. Q Rev Biophys. 41:41–101. 2008.PubMed/NCBI
|
|
2
|
Li TK and Liu LF: Tumor cell death induced
by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol.
41:53–77. 2001.PubMed/NCBI
|
|
3
|
Wu CP, Calcagno AM and Ambudkar SV:
Reversal of ABC drug transporter-mediated multidrug resistance in
cancer cells: Evaluation of current strategies. Curr Mol Pharmacol.
1:93–105. 2008.PubMed/NCBI
|
|
4
|
Velasquez WS, Lew D, Grogan TM,
Spiridonidis CH, Balcerzak SP, Dakhil SR, Miller TP, Lanier KS,
Chapman RA and Fisher RI; Southwest Oncology Group, : Combination
of fludarabine and mitoxantrone in untreated stages III and IV
low-grade lymphoma: S9501. J Clin Oncol. 21:1996–2003.
2003.PubMed/NCBI
|
|
5
|
Gotwals P, Cameron S, Cipolletta D,
Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S,
Sabatos-Peyton C, Petruzzelli L, et al: Prospects for combining
targeted and conventional cancer therapy with immunotherapy. Nat
Rev Cancer. 17:286–301. 2017.PubMed/NCBI
|
|
6
|
Johnson BE: Concurrent approaches to
combined chemotherapy and chest radiotherapy for the treatment of
patients with limited stage small cell lung cancer. Lung Cancer. 10
(Suppl 1):S281–S287. 1994.PubMed/NCBI
|
|
7
|
Zhu Y, Liu C, Armstrong C, Lou W, Sandher
A and Gao AC: Antiandrogens inhibit ABCB1 Efflux and ATPase
activity and reverse docetaxel resistance in advanced prostate
cancer. Clin Cancer Res. 21:4133–4142. 2015.PubMed/NCBI
|
|
8
|
Palmeira A, Sousa E, Vasconcelos MH and
Pinto MM: Three decades of P-gp inhibitors: Skimming through
several generations and scaffolds. Curr Med Chem. 19:1946–2025.
2012.PubMed/NCBI
|
|
9
|
Chen Z, Shi T, Zhang L, Zhu P, Deng M,
Huang C, Hu T, Jiang L and Li J: Mammalian drug efflux transporters
of the ATP binding cassette (ABC) family in multidrug resistance: A
review of the past decade. Cancer Lett. 370:153–164.
2016.PubMed/NCBI
|
|
10
|
Yuan H, Li X, Wu J, Li J, Qu X, Xu W and
Tang W: Strategies to overcome or circumvent P-glycoprotein
mediated multidrug resistance. Curr Med Chem. 15:470–476.
2008.PubMed/NCBI
|
|
11
|
Bomke C and Tudzynski B: Diversity,
regulation, and evolution of the gibberellin biosynthetic pathway
in fungi compared to plants and bacteria. Phytochemistry.
70:1876–1893. 2009.PubMed/NCBI
|
|
12
|
Chen J, Sun Z, Zhang Y, Zeng X, Qing C,
Liu J, Li L and Zhang H: Synthesis of gibberellin derivatives with
anti-tumor bioactivities. Bioorg Med Chem Lett. 19:5496–5499.
2009.PubMed/NCBI
|
|
13
|
Zhang Y, Zhang H, Chen J, Zhao H, Zeng X,
Zhang H and Qing C: Antitumor and antiangiogenic effects of
GA-13315, a gibberellin derivative. Invest New Drugs. 30:8–16.
2012.PubMed/NCBI
|
|
14
|
Mo J, Kang M, Ye JX, Chen JB, Zhang HB and
Qing C: Gibberellin derivative GA-13315 sensitizes
multidrug-resistant cancer cells by antagonizing ABCB1 while
agonizes ABCC1. Cancer Chemother Pharmacol. 78:51–61.
2016.PubMed/NCBI
|
|
15
|
Das SG, Hermanson DL, Bleeker N, Lowman X,
Li Y, Kelekar A and Xing C: Ethyl
2-amino-6-(3,5-dimethoxyphenyl)-4-
(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): A novel
scaffold that resensitizes multidrug resistant leukemia cells to
chemotherapy. ACS Chem Biol. 8:327–335. 2013.PubMed/NCBI
|
|
16
|
Walker JM: The bicinchoninic acid (BCA)
assay for protein quantitation. Methods Mol Biol. 32:5–8.
1994.PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI
|
|
18
|
Sabisz M, Wesierska-Gadek J and
Skladanowski A: Increased cytotoxicity of an unusual DNA
topoisomerase II inhibitor compound C-1305 toward HeLa cells with
downregulated PARP-1 activity results from re-activation of the p53
pathway and modulation of mitotic checkpoints. Biochem Pharmacol.
79:1387–1397. 2010.PubMed/NCBI
|
|
19
|
Patra N, De U, Kang JA, Kim JM, Ahn MY,
Lee J, Jung JH, Chung HY, Moon HR and Kim HS: A novel epoxypropoxy
flavonoid derivative and topoisomerase II inhibitor, MHY336,
induces apoptosis in prostate cancer cells. Eur J Pharmacol.
658:98–107. 2011.PubMed/NCBI
|
|
20
|
Champoux JJ: DNA topoisomerases:
Structure, function, and mechanism. Annu Rev Biochem. 70:369–413.
2001.PubMed/NCBI
|
|
21
|
Peterson KE, Cinelli MA, Morrell AE, Mehta
A, Dexheimer TS, Agama K, Antony S, Pommier Y and Cushman M:
Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines
as topoisomerase I inhibitors: Investigating the relationships
involving stereochemistry, hydrogen bonding, and biological
activity. J Med Chem. 54:4937–4953. 2011.PubMed/NCBI
|
|
22
|
Chen AY and Liu LF: DNA topoisomerases:
Essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol.
34:191–218. 1994.PubMed/NCBI
|
|
23
|
Hsiang YH, Lihou MG and Liu LF: Arrest of
replication forks by drug-stabilized topoisomerase I-DNA cleavable
complexes as a mechanism of cell killing by camptothecin. Cancer
Res. 49:5077–5082. 1989.PubMed/NCBI
|
|
24
|
Liu LF, Desai SD, Li TK, Mao Y, Sun M and
Sim SP: Mechanism of action of camptothecin. Ann NY Acad Sci.
922:1–10. 2000.PubMed/NCBI
|
|
25
|
Irinotecan, . Drugs and Lactation Database
(LactMed) National Library of Medicine (US). Bethesda, MD: 2006
|
|
26
|
Gilbert DC, Chalmers AJ and El-Khamisy SF:
Topoisomerase I inhibition in colorectal cancer: Biomarkers and
therapeutic targets. Br J Cancer. 106:18–24. 2012.PubMed/NCBI
|
|
27
|
Li F, Jiang T, Li Q and Ling X:
Camptothecin (CPT) and its derivatives are known to target
topoisomerase I (Top1) as their mechanism of action: Did we miss
something in CPT analogue molecular targets for treating human
disease such as cancer? Am J Cancer Res. 7:2350–2394.
2017.PubMed/NCBI
|
|
28
|
El-Khamisy SF, Hartsuiker E and Caldecott
KW: TDP1 facilitates repair of ionizing radiation-induced DNA
single-strand breaks. DNA Repair (Amst). 6:1485–1495.
2007.PubMed/NCBI
|
|
29
|
El-Khamisy SF, Saifi GM, Weinfeld M,
Johansson F, Helleday T, Lupski JR and Caldecott KW: Defective DNA
single-strand break repair in spinocerebellar ataxia with axonal
neuropathy-1. Nature. 434:108–113. 2005.PubMed/NCBI
|
|
30
|
Pommier Y, Barcelo JM, Rao VA, Sordet O,
Jobson AG, Thibaut L, Miao ZH, Seiler JA, Zhang H, Marchand C, et
al: Repair of topoisomerase I-mediated DNA damage. Prog Nucleic
Acid Res Mol Biol. 81:179–229. 2006.PubMed/NCBI
|
|
31
|
Feijoo C, Hall-Jackson C, Wu R, Jenkins D,
Leitch J, Gilbert DM and Smythe C: Activation of mammalian Chk1
during DNA replication arrest: A role for Chk1 in the intra-S phase
checkpoint monitoring replication origin firing. J Cell Biol.
154:913–923. 2001.PubMed/NCBI
|
|
32
|
Zachos G, Rainey M and Gillespie DA:
Lethal errors in checkpoint control-life without Chk1. Cell Cycle.
2:14–16. 2003.PubMed/NCBI
|
|
33
|
Liu C, Zhou S, Begum S, Sidransky D,
Westra WH, Brock M and Califano JA: Increased expression and
activity of repair genes TDP1 and XPF in non-small cell lung
cancer. Lung Cancer. 55:303–311. 2007.PubMed/NCBI
|
|
34
|
Dean RA, Fam HK, An J, Choi K, Shimizu Y,
Jones SJ, Boerkoel CF, Interthal H and Pfeifer TA: Identification
of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based
assays. J Biomol Screen. 19:1372–1382. 2014.PubMed/NCBI
|
|
35
|
Pommier Y and Cushman M: The
indenoisoquinoline noncamptothecin topoisomerase I inhibitors:
Update and perspectives. Mol Cancer Ther. 8:1008–1014.
2009.PubMed/NCBI
|
|
36
|
Zhang YW, Otterness DM, Chiang GG, Xie W,
Liu YC, Mercurio F and Abraham RT: Genotoxic stress targets human
Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell.
19:607–618. 2005.PubMed/NCBI
|
|
37
|
Walensky LD: BCL-2 in the crosshairs:
Tipping the balance of life and death. Cell Death Differ.
13:1339–1350. 2006.PubMed/NCBI
|
|
38
|
Tsukahara S, Yamamoto S, Tin-Tin-Win-Shwe,
Ahmed S, Kunugita N, Arashidani K and Fujimaki H: Inhalation of
low-level formaldehyde increases the Bcl-2/Bax expression ratio in
the hippocampus of immunologically sensitized mice.
Neuroimmunomodulation. 13:63–68. 2006.PubMed/NCBI
|
|
39
|
Xu C, Xu W, Palmer AE and Reed JC: BI-1
regulates endoplasmic reticulum Ca2+ homeostasis
downstream of Bcl-2 family proteins. J Biol Chem. 283:11477–11484.
2008.PubMed/NCBI
|
|
40
|
Lo YL and Liu Y: Reversing multidrug
resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and
BCL-2/BCL-xL using liposomal antisense oligonucleotides. PLoS One.
9:e901802014.PubMed/NCBI
|
|
41
|
Liaud N, Horlbeck MA, Gilbert LA, Gjoni K,
Weissman JS and Cate JHD: Cellular response to small molecules that
selectively stall protein synthesis by the ribosome. PLoS Genet.
15:e10080572019.PubMed/NCBI
|
|
42
|
Watters DJ: Ascidian toxins with potential
for drug development. Mar Drugs. 16:1622018.
|
|
43
|
Pavitt GD: Regulation of translation
initiation factor eIF2B at the hub of the integrated stress
response. Wiley Interdiscip Rev RNA. 9:e14912018.PubMed/NCBI
|
